title: Decreased expression of TFPI-2 correlated with increased expression of CD133 in cholangiocarcinoma.
abstract: BACKGROUND
  Recent findings suggest decreasing TFPI-2 expression plays a significant role in inhibiting cell migration and tumor invasion. The clinicopathological significance of the expression of TFPI-2 and its possible correlation with the expression of CD133 in cholangiocarcinoma remains to be solved.
  
  
  METHODS
  We investigated if TFPI-2 was involved in the clinicopathological significance of cholangiocarcinoma. An immunohistochemical method was used to detect 218 cases of cholangiocarcinoma, 30 para-neoplastic and 20 normal bile ducts for their expression status of TFPI-2 and CD133, and then the results were analyzed with the patient's age, sex, tumor site and the histological grade, clinical stage as well as overall mean survival time.
  
  
  RESULTS
  Compared with the para-neoplastic and normal cholangiocytes, the expression of TFPI-2 was obviously decreased while the expression of CD133 in carcinoma cells was increased. Carcinomas with low expression of TFPI-2 were significantly corresponding to the tumor site (P = 0.006), size (P = 0.005), histological grade (P = 0.0001) and clinical stage (P = 0.0001), but not to the age (P = 0.066) and sex (P = 0.411), respectively. By Kaplan-Meier survival analysis, the low expression of TFPI-2 was significantly correlative with the overall survival time (P = 0.0001). Further, the expression of TFPI-2 was found inversely correlative with the expression of CD133 (g = -0.3876, P < 0.0001).
  
  
  CONCLUSIONS
  Our finding suggests that the decreased expression of TFPI-2 may play an important role in the carcinogenesis and progression, and may become a new adjunct marker in the diagnosis and prognosis in cholangiocarcinoma. The expression of TFPI-2 may be inversely correlative with the expression of CD133.
authors.affiliation: Department of Pathology, 153 Hospital of PLA Zhengzhou 450042, China ; Department of Pathology, PLA General Hospital 28 Fuxing Road, Beijing 100853, China.
authors.forename: Xia
authors.initials: X
authors.lastname: Chu
authors.affiliation: Department of Pathology, PLA General Hospital 28 Fuxing Road, Beijing 100853, China.
authors.forename: Po
authors.initials: P
authors.lastname: Zhao
authors.affiliation: Department of Pathology, PLA General Hospital 28 Fuxing Road, Beijing 100853, China.
authors.forename: Yali
authors.initials: Y
authors.lastname: Lv
authors.affiliation: Department of Pathology, PLA General Hospital 28 Fuxing Road, Beijing 100853, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Liu
mesh_terms: D000071916:AC133 Antigen; D015703:Antigens, CD / Q000096:biosynthesis*; D001650:Bile Duct Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D014408:Biomarkers, Tumor / Q000032:analysis; D018281:Cholangiocarcinoma / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D006023:Glycoproteins / Q000096:biosynthesis*; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010455:Peptides; D011379:Prognosis; D016016:Proportional Hazards Models
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D014408:Biomarkers, Tumor; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides; C021240:tissue-factor-pathway inhibitor 2
keywords: CD133; Cholangiocarcinoma; TFPI-2; immunohistochemistry; prognosis